Get ready for a wave of buyouts in biotech

Big pharma is set to snap up smaller firms as consolidation comes to the pharmaceutical industry. That will be a great opportunity for investors. Bengt Saelensminde explains why - and what you should look out for.

Here's something I've learned about investing over the years: while there is always a risk that a stock you invest in goes bust destroying your investment in the process it doesn't happen very often.

What's much more likely to damage your wealth is the insidious effect of fundraisings.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Swipe to scroll horizontally
IBT (Schroder's)10110111976.2
BIOG (Orbimed)106127162120
Orbimed outperformance5%26%36%57%

Bengt graduated from Reading University in 1994 and followed up with a master's degree in business economics.

 

He started stock market investing at the age of 13, and this eventually led to a job in the City of London in 1995. He started on a bond desk at Cantor Fitzgerald and ended up running a desk at stockbroker's Cazenove.

 

Bengt left the City in 2000 to start up his own import and beauty products business which he still runs today.